TORL-1-23 is an investigational therapy being studied for the treatment of advanced ovarian cancer, including cancers of the fallopian tubes and peritoneum (the lining of the abdominal cavity). This medication targets a specific protein called Claudin 6 (CLDN6) that is found in certain types of ovarian cancer cells. It is being tested as a single therapy in women whose cancer has become resistant to platinum-based chemotherapy treatments.

Peritoneal Cancer – A condition where cancerous cells develop in the peritoneum, the thin layer of tissue that lines the inside of the abdomen and covers most abdominal organs. The cancer can form as small nodules or masses throughout the peritoneal cavity. This type of cancer can spread across the peritoneal surfaces and affect multiple organs within the abdominal cavity.

Ovarian Cancer – A disease in which abnormal cells develop in the ovaries, the female reproductive organs that produce eggs. The cancer typically begins in the outer layer of the ovaries. As it progresses, cancer cells can spread within the pelvis and abdomen. The disease often develops without noticeable early symptoms.

Fallopian Tube Cancer – A rare cancer that develops in the fallopian tubes, the structures that connect the ovaries to the uterus. The cancer begins in the cells lining the fallopian tubes. As the disease advances, abnormal cells multiply and can spread to nearby structures. This cancer shares many similarities with ovarian cancer in terms of its behavior and progression.